Erratum: Intravenous ketamine for adolescents with treatment-resistant depression: An Open-Label Study, by Cullen KR, Amatya P, Roback MG, Albott CS, Westlund Schreiner M, Ren Y, Eberly LE, Carstedt P, Samikoglu A, Gunlicks-Stoessel M, Reigstad K, Horek N, Tye S, Lim KO, Klimes-Dougan B. (J Child Adolesc Psychopharmacol (2018) 28:7 (437-444) DOI: 10.1089/cap.2018.0030)

In the September 2018 issue of Journal of Child and Adolescent Psychopharmacology (vol. 28, no. 7, pp. 437-444), the article "Intravenous Ketamine for Adolescents with Treatment-Resistant Depression: An Open-Label Study," by Dr. Kathryn R. Cullen et al., was missing the financial support information as follows: This research was supported by the National Institutes of Health's National Center for Advancing Translational Sciences (UL1TR002494), the Biotechnology Research Center (P41 EB015 894), the NINDS Institutional Center Core Grants to Support Neuroscience Research (P30 NS076408), the High Performance Connectome Upgrade for Human 3TMR Scanner (1S10OD017974-01), and the University Foundation, Amplatz Scholarship. The online version of the article has been corrected to reflect this additional information. The authors wish to apologize for the omission